Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342426 | 0.89 | TAAR1 (0.55) | PARP1FOLH1MEP1BLOXL2HTR6 | |
| Hydrochloric Acid SCHEMBL28744996 | 0.87 | TAAR1 (0.53) | PARP1FOLH1MEP1BLOXL2HTR6 | |
| SCHEMBL7556820 | 0.86 | FOLH1 (0.58) | FOLH1HTR6 | |
| SCHEMBL14629791 | 0.86 | CYP4F2 (0.60) | PARP1FOLH1MEP1BCYP4F2CYP4A11 | |
| SCHEMBL2822360 | 0.84 | PARP1 (0.50) | PARP1FOLH1MEP1BCYP4F2CYP4A11 | |
| SCHEMBL5194309 | 0.84 | SPHK2 (0.52) | PARP1FOLH1MEP1BCYP4F2CYP4A11 | |
| SCHEMBL10669113 | 0.83 | SPHK2 (0.57) | PARP1CYP4F2CYP4A11 | |
| SCHEMBL3054119 | 0.81 | CYP4F2 (0.62) | PARP1FOLH1MEP1BCYP4F2CYP4A11 | |
| SCHEMBL10189495 | 0.81 | PARP1 (0.56) | PARP1FOLH1MEP1BOPRM1OPRD1 | |
| SCHEMBL7462073 | 0.81 | CYP4F2 (0.47) | PARP1FOLH1MEP1BCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0658538-B1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA INC (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0329464-B1 | System for the closed-loop administration of an exercise simulating agent | GENSIA INC (US) | 1995-11-02 | — | — | EP | disclosed |
| US-5460605-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0658538-A1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5395970-A | 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol | GENSIA PHARMACEUTICALS, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5286252-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| US-5234404-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5108363-A | DIAGNOSIS, EVALUATION AND TREATMENT OF CORONARY ARTERY DISEASE BY EXERCISE SIMULATION USING CLOSED LOOP DRUG DELIVERY OF AN EXERCISE SIMULATING AGENT BETA AGONIST | GENSIA PHARMACEUTICALS, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0329464-A2 | System for the closed-loop administration of an exercise simulating agent | GENSIA, INC. (US) | 1989-08-23 | — | — | EP | disclosed |